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Purpose: Mutations in the myocilin gene (MYOC) account for 2%–4% of primary open angle glaucoma (POAG) cases.
To date, a limited number of Indian POAG patients have been analyzed for the contribution of the gene towards the disease
pathogenesis. In this study we provided a comprehensive analysis of a total of 765 eastern Indian POAG patients.
Methods: In the present study 450 POAG patients and 208 ethnically matched controls were screened for the coding
region of MYOC by using the polymerase chain reaction-direct sequencing approach; 315 POAG patients were analyzed
in a previous study. Thus, our total patient cohort considering both the studies was 765. In addition, 1 kb upstream region
of the gene was also examined for variants in a subset of 250 patients and 100 control samples.
Results: Analysis of MYOC coding regions in 450 POAG patients revealed 10 novel variations including 2 frame-shift
(R125SfsX158 and D273DfsX344) and 3 nonsynonymous changes (Arg33Lys, Ser331Leu, and Asp395Glu), 3 reported
mutations and 4 reported polymorphisms. Gln48His, which has to date been reported only from Indian subcontinent, was
identified in 4 individuals among 450 patients, taking the count to 7 individuals among 765 patients harboring the same
mutation in eastern Indian cohort. Screening of 1 kb upstream region of MYOC in limited number of individuals yielded
5 variants but none are likely to contribute to the pathogenesis of the disease.
Conclusions: MYOC mutations were found to account for 3% of POAG cases in our entire cohort (n=765) and Gln48His
is the most common defect. This study, for the first time, reports the presence of deletion mutations in Indian patients,
and represents the largest study performed in a single cohort in the Indian population.
Glaucoma affects approximately 70 million people and
is  the  second  leading  cause  of  irreversible  blindness
worldwide [1]. Among the various subtypes, primary open-
angle glaucoma (POAG) is the most common form of this
disease.
POAG is a mutifactorial complex disorder where both
environmental and genetic factors precipitate the disease. It
has  been  suggested  that  72%  of  POAG  cases  have  some
familial component [2], but on rare occasion it follows a
Mendelian  pattern  of  inheritance,  including  juvenile  open
angle  glaucoma  (JOAG)  cases.  It  is  characterized  by
progressive loss of retinal ganglion cells and atrophy of the
optic nerve head, often associated with elevated intraocular
pressure (IOP) caused by the reduced outflow of aqueous
humor through the trabecular meshwork (TM), a meshwork
of tissue lining the outflow pathway at the iridocorneal angle
of the anterior chamber of the eye [3,4].
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The complexity of POAG has recently been reviewed
[5,6]. To date, 33 loci have been reported to be linked with
POAG, but only three underlying genes have been identified:
viz, myocilin (MYOC) [7], optineurin (OPTN) [8], and WD
repeat domain 36 (WDR36) [9]. Also, heterozygous mutations
in neurotrophin 4 (NTF4) have been reported in sporadic
POAG patients [10,11], however, its involvement in POAG
pathogenesis  remains  controversial  [12,13].  In  addition,
recent studies show involvement of CYP1B1 in POAG in spite
of its being a candidate gene for primary congenital glaucoma
(PCG) [14-16].
Myocilin was the first gene found to be linked to POAG
[7]. It is located in chromosome 1 spanning a region of 17 kb.
It contains three exons and is expressed as a 2.3-kb transcript
with the translated product of 504 amino acids [17]. Most of
the disease-causing mutations have been found in the third
exon, a few in the first exon but none in the second exon.
Myocilin mutants are known to cause glaucoma by gain of
function [18], though the exact pathophysiology underlying
MYOC  mediated  glaucoma  pathogenesis  is  yet  to  be
elucidated.  However,  it  has  been  hypothesized  that  an
increased level of myocilin as well as mutated form of the
protein  forms  aggregates  within  the  trabecular  meshwork
(TM) activating the unfolded protein response (UPR), finally
resulting in malfunction or death of TM cells [19]. It has also
been proposed that MYOC appears in the extracellular space
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1548of  trabecular  meshwork  cells  by  an  unconventional
mechanism likely to be associated with the exosome [20].
Mutations in MYOC are the most widely studied and
account for 2%–4% of POAG cases and around 33% of JOAG
cases [7,21-24]. Two previous studies from our laboratory
also showed similar contribution of the gene [25,26]. In this
study,  we  further  analyzed  the  involvement  of  myocilin
variants  in  450  additional  POAG  patients  with  a  familial
history of glaucoma or high intraocular pressure and have
provided a comprehensive analysis of a total of 765 eastern
Indian POAG patients.
METHODS
Selection of study subjects: Eastern Indian POAG patients and
control  subjects  from  Kolkata,  West  Bengal,  speaking
Bengali, and belonging to the Indo-European linguistic group,
were recruited from the Dristipradip Eye Clinic, Kolkata,
India.
Identification of POAG patients and controls involved
clinical,  ocular  and  systemic  examinations.  Intraocular
pressure  (IOP)  was  measured  by  Goldmann  applanation
tonometry (Haag-Streit USA Inc., Mason, OH) followed by
pachymetry (Ocuscan A; Alcon, Fort Worth, TX). The angles
of anterior chamber and optic disc were assessed using a
Goldmann  3-mirror  gonioscope  (Ocular  Instrument,
Bellevue, WA). The optic disc was also evaluated with a +78D
lens. Automated threshold field analysis was done using the
Humphrey Field Analyzer II (Carl Zeiss, Dublin, CA). The
retinal nerve fiber layer (RNFL) was investigated by Scanning
Laser Polarimetry (SLP) with variable corneal compensation
technique (GDx-Vcc; Carl Zeiss, Dublin, CA).
POAG  patients  diagnosis  was  based  on  an  increased
intraocular pressure above 21 mmHg, significant cupping of
the optic disc (>0.7) with or without peripapillary changes and
the presence of clinically open angle (angle of the anterior
chamber) on Gonioscopy. Though increased IOP is not an
indicator  of  diseased  status,  MYOC  mediated  POAG
pathogenesis is often associated with elevated IOP [27-29].
The  suspicion  of  POAG  was  confirmed  by  typical
reproducible  visual  field  changes,  viz.  arcuate,  Bjerrum,
Seidel, paracentral, and annular scotoma and nasal steps and
Scanning Laser Polarimetry for RNFL analysis (Nerve Fiber
Indicator>30). The pre-perimetric cases were identified by
RNFL  analysis.  The  IOP,  in  each  case  was  corrected  for
central corneal thickness (CCT). Individuals with any history
of  inflammation,  ocular  trauma  (past  and  present),  high
myopia (>8 diopter) and ocular hypertension were excluded
from this study. The patient pool consisted of 450 primary
open angle glaucoma cases, including 44 juvenile onset cases.
The age at diagnosis ranged from 15 to 88 years (mean age
±SD, 57.03±12.44 years). The patients were not known to
have any other eye disorder.
The controls subjects had an age >50 years (mean age
±SD, 57.3±9.7 years), without any family history of glaucoma
or  ocular  hypertension,  IOP  was  considered  to  be  within
normal range i.e., <20 mmHg in both eyes, CCT ranging from
500 μm to 580 μm in both eyes with no visual field defect and
normal Scanning Laser Polarimeter (SLP) parameters; These
include a good yellowish bow-tie scan pattern, deviation map
within  normal  limit,  a  good  double  hump  pattern  in
conduction  map,  temporal-superior-nasal-inferior-temporal
(TSNIT)  parameters  within  normal  limit,  Nerve  Fiber
Indicator  (Index)  <30  for  both  eyes.  Cup  to  disc  ratio
considered was <0.5 and similar in both eyes, with no defect
in disc rim or margin and no sphincter hemorrhage around the
disc. Individuals with high myopia (> 8 diopter), diabetes and
hypertension were excluded from the control group. The study
protocol adhered to the tenets of the Declaration of Helsinki
and was approved by the Institutional Review Board.
Collection of blood samples and genomic DNA preparation:
Eight milliliters of peripheral blood was collected from the
POAG  patients  and  normal  individuals  with  their  written
consent and transported with anticoagulant. Genomic DNA
was prepared from fresh whole blood using the PAX gene
blood  DNA  isolation  kit  (Qiagen,  Hilden,  Germany)
according to the manufacturer’s protocol.
Polymerase  chain  reaction  and  DNA  sequencing:  PCR
reactions were performed in 20 μl reaction volumes using 80
ng of genomic DNA with Ex Prime Taq Premix (GeNet Bio,
Chungnam, South Korea) to amplify exons and adjoining
splice junctions using primers listed in Table 1. Briefly, each
exon was amplified with an initial denaturation at 94 °C for 5
min, followed by 35 cycles of denaturation at 94 °C for 30 s,
annealing at 58 °C for 30 s, and extension at 72 °C for 30 s.
A final extension at 72 °C for 5 min completed the reaction.
The PCR products (5 μl) were analyzed by electrophoresis in
1% agarose. Briefly, specific PCR products were purified and
subjected to bi-directional sequencing with primers listed in
Table 1, using an ABI 3130XL DNA sequencer with dye
termination chemistry to identify any alteration of sequence.
Bioinformatic analysis: Novel changes were evaluated for
their  potential  effect  on  the  protein  product  using  SIFT
(sorting intolerant from tolerant) and Polyphen-2. The SIFT
software predicts whether an amino acid substitution affects
protein function. The effect of the substitution on the protein
structure was assessed by PolyPhen-2.
RESULTS
Analysis of MYOC coding regions in POAG patients revealed
17  changes  including  10  novel  variations,  3  reported
mutations  and  4  reported  polymorphisms.  The  mutations,
polymorphisms and rare variants identified in POAG patients
are  listed  in  Table  2  and  Table  3,  respectively,  with  the
genotype and in silico evaluations of the variants. The clinical
phenotypes of the patients detected with mutations in the
present study are given in Table 4.
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1549Among  the  novel  variants  identified,  c.98G>A,
Arg33Lys was identified in a 64-year-old glaucoma patient
with a positive family history of glaucoma (Table 4). Due to
a  lack  of  family  members  we  could  not  ascertain  the
pathogenic effect of this variation.
A frameshift mutation c.375 Del G, R125SfsX158 was
identified in MYOC exon 1 (Figure 1A). The patient (GL883)
was detected with POAG at 67 years of age and a positive
family history (Table 4) with both the elder brother and sister
being affected. Clinical examination revealed that she has
severe visual field defect with high cup disc ratio in both eyes
(RE>LE). Analysis of the blood samples from her son and
daughter showed the presence of the probable disease causing
mutation in her 42-year-old daughter. However, there were no
early signs of glaucoma. Another novel frameshift mutation
c.819  Del  C,  D273DfsX344  in  exon  3  (Figure  1B)  was
identified  in  a  64-year-old  POAG  patient  (GL1129)  with
positive family history (Table 4). Apart from the proband, his
27-year-old daughter harbored the same nucleotide change
and had an IOP of 23 mmHg and 21 mmHg with a cup:disc
ratio of 0.3 and 0.2 in her right and left eyes, respectively. She
was phenotypically normal. However, she was advised to be
under constant supervision at regular intervals. By conceptual
translation of the transcript both these frameshift mutations
are predicted to result in early truncation of MYOC.
A  c.992C>T,  Ser331Leu  variant  (Figure  1C)  was
identified  in  a  61-year-old  male  patient  (GL1208)  with  a
positive family history of glaucoma (Table 4), with his late
father  being  affected  with  severe  glaucoma  phenotype.
Analysis of blood samples from his family members showed
that the absence of the variation in his son and daughter. The
variation involves replacement of an evolutionarily conserved
amino acid by a nonconservative change of the residue, which
was not detected in the controls. A previous study from south
India identified a change to threonine at the same position
[30].
The novel variation c.1185T>G, Asp395Glu in MYOC
exon 3 was identified in two unrelated adult onset glaucoma
cases (Table 4), both of whom were heterozygous for the
change. The change is assessed to be benign by in silico
analysis.
Among  the  reported  mutations,  c.144G>T,  Gln48His,
which has only been reported from the Indian subcontinent to
date [23,26,31,32], was identified in 4 of the 450 POAG
patients analyzed in the current study. Thus, to date, 7 (4
POAG & 3 JOAG) out of 765 patients in the eastern Indian
cohort  were  found  to  harbor  the  same  mutation.  All  the
identified individuals were high tension glaucoma patients,
which points toward the pathogenic effect of the mutation
resulting in a severe phenotype. A Triton-X-100 assay [33],
done  using  recombinant  myocilin  containing  the  variant
residue (His) shows aggregation, confirming the deleterious
effect of the mutation (unpublished). Genotyping done with
the microsattelite markers DIS2815 and DIS2790 and −83G/
A single nucleotide polymorphism (SNP) in MYOC suggests
that the mutation might have originated multiple times in
different haplotype backgrounds.
In the course of the study, c.767C>T, Thr256Met was
identified  in  two  POAG  patients  in  heterozygous  state.
Interestingly, both these individuals had no family history of
glaucoma. The age at diagnosis was similar (43 years and 46
years) with enlargement of blind spots. This similarity in
disease  phenotype  points  toward  a  potentially  common
underlying  pathophysiology  of  the  mutation.  Although
Polyphen  analysis  predicts  this  variant  to  be  a  benign
polymorphism, the threonine residue is found to be conserved
across different species. The Thr256Met change has also been
reported in a single patient from a study of normal tension
glaucoma [34]. However, that study did not provide a detailed
clinical description of the patient for further analysis. Unlike
simple Mendelian disorders, glaucoma is a complex disease,
and it is quite possible that the variants predicted to be benign
might act as modifiers under a permissible environment, and
thus might show varying levels of penetrance in the family.
A c.1102C>T, Gln368Stop mutation was identified in a
patient  (GL1117)  with  high  intraocular  pressure  of
41.3  mmHg  (RE)  and  47  mmHg  (LE).  Presence  of  this
mutation has previously been reported from our laboratory in
TABLE 1. PRIMERS USED FOR PCR AND SEQUENCING OF THE MYOC CODING REGION.
Primer ID Location Primer sequences Tm Ampilcon Size (bp)
PCR primers
TIGR-1F Exon 1 5'- GGCTGGCTCCCCAGTATATA -3' 62 762
TIGR-6R   5'- CTGCTGAACTCAGAGTCCCC -3' 64  
TIGR-8F Exon 3 5'- TTATGGATTAAGTGGTGCTTCG -3' 54 860
TIGR-13R   5'- AGCATCTCCTTCTGCCATTG -3' 60  
Sequencing primers
TIGR-3F Exon 1 5'-AGTGGCCGATGCCAGTATAC-3' 62  
TIGR-3R   5'-CTGGTCCAAGGTCAATTGGT-3' 60  
TIGR-10F Exon 3 5'- ATACTGCCTAGGCCACTGGA-3' 62  
TIGR-10R   5'- CAATGTCCGTGTAGCCACC -3' 62  
Molecular Vision 2012; 18:1548-1557 <http://www.molvis.org/molvis/v18/a160> © 2012 Molecular Vision
1550T
A
B
L
E
 
2
.
 
M
U
T
A
T
I
O
N
S
 
I
D
E
N
T
I
F
I
E
D
 
I
N
 
M
Y
O
C
 
I
N
 
E
A
S
T
E
R
N
 
I
N
D
I
A
N
 
P
O
A
G
 
P
A
T
I
E
N
T
S
.
 
 
 
 
 
 
N
u
m
b
e
r
 
o
f
E
x
o
n
N
u
c
l
e
o
t
i
d
e
c
h
a
n
g
e
A
m
i
n
o
 
a
c
i
d
 
c
h
a
n
g
e
S
t
a
t
u
s
S
I
F
T
s
c
o
r
e
P
o
l
y
p
h
e
n
 
p
r
e
d
i
c
t
i
o
n
 
(
S
c
o
r
e
)
P
a
t
i
e
n
t
s
 
(
M
A
F
)
C
o
n
t
r
o
l
s
 
(
M
A
F
)
E
x
o
n
 
1
c
.
1
4
4
G
>
T
G
l
n
4
8
H
i
s
†
R
e
p
o
r
t
e
d
0
.
0
9
P
o
s
s
i
b
l
y
 
d
a
m
a
g
i
n
g
 
(
0
.
9
5
7
)
7
/
7
6
5
 
(
0
.
0
0
4
6
)
0
/
2
0
8
 
c
.
3
7
5
 
D
e
l
 
G
R
1
2
5
f
s
X
1
5
8
N
o
v
e
l
-
-
1
/
7
6
5
 
(
0
.
0
0
0
6
5
)
0
/
2
0
8
 
c
.
7
6
7
C
>
T
T
h
r
2
5
6
M
e
t
†
R
e
p
o
r
t
e
d
0
.
1
5
B
e
n
i
g
n
 
(
0
.
2
2
9
)
2
/
7
6
5
 
(
0
.
0
0
1
3
)
0
/
2
0
8
 
c
.
8
1
9
 
D
e
l
 
C
D
2
7
3
f
s
X
3
4
4
N
o
v
e
l
-
-
1
/
7
6
5
 
(
0
.
0
0
0
6
5
)
0
/
2
0
8
 
c
.
9
9
2
C
>
T
S
e
r
3
3
1
L
e
u
N
o
v
e
l
0
.
1
8
B
e
n
i
g
n
 
(
0
.
0
6
6
)
1
/
7
6
5
 
(
0
.
0
0
0
6
5
)
0
/
2
0
8
E
x
o
n
 
3
c
.
1
1
0
2
C
>
T
G
l
n
3
6
8
S
t
o
p
†
R
e
p
o
r
t
e
d
-
-
3
/
7
6
5
 
(
0
.
0
0
1
9
)
0
/
2
0
8
 
c
.
1
1
0
9
C
>
T
P
r
o
3
7
0
L
e
u
‡
R
e
p
o
r
t
e
d
0
.
0
3
P
r
o
b
a
b
l
y
 
d
a
m
a
g
i
n
g
 
(
1
.
0
0
0
)
1
/
7
6
5
 
(
0
.
0
0
0
6
5
)
0
/
2
0
8
 
c
.
1
1
9
6
G
>
A
G
l
y
3
9
9
A
s
p
‡
R
e
p
o
r
t
e
d
0
.
0
0
P
r
o
b
a
b
l
y
 
d
a
m
a
g
i
n
g
 
(
1
.
0
0
0
)
1
/
7
6
5
 
(
0
.
0
0
1
3
)
0
/
2
0
8
 
c
.
1
2
7
9
G
>
A
A
l
a
4
2
7
T
h
r
‡
R
e
p
o
r
t
e
d
0
.
0
2
P
r
o
b
a
b
l
y
 
d
a
m
a
g
i
n
g
 
(
1
.
0
0
0
)
2
/
7
6
5
 
(
0
.
0
0
1
3
)
0
/
2
0
8
F
r
o
m
 
a
 
c
o
h
o
r
t
 
o
f
 
7
6
5
 
P
O
A
G
 
p
a
t
i
e
n
t
s
,
 
4
5
0
 
D
N
A
 
s
a
m
p
l
e
s
 
w
e
r
e
 
s
c
r
e
e
n
e
d
 
f
o
r
 
t
h
e
 
c
o
d
i
n
g
 
r
e
g
i
o
n
 
o
f
 
M
Y
O
C
 
i
n
 
t
h
e
 
p
r
e
s
e
n
t
 
s
t
u
d
y
;
 
t
h
e
 
r
e
m
a
i
n
i
n
g
 
3
1
5
 
h
a
v
e
 
b
e
e
n
 
a
n
a
l
y
z
e
d
b
e
f
o
r
e
 
[
2
5
]
.
 
U
n
r
e
l
a
t
e
d
 
c
o
n
t
r
o
l
 
s
u
b
j
e
c
t
s
 
(
n
=
2
0
8
)
 
w
e
r
e
 
e
n
r
o
l
l
e
d
 
f
r
o
m
 
t
h
e
 
s
a
m
e
 
e
t
h
n
i
c
 
b
a
c
k
g
r
o
u
n
d
.
 
M
A
F
:
 
M
i
n
o
r
 
A
l
l
e
l
e
 
F
r
e
q
u
e
n
c
y
.
 
G
e
n
o
t
y
p
e
s
 
f
o
r
 
a
l
l
 
m
u
t
a
t
i
o
n
s
 
a
r
e
h
e
t
e
r
o
z
y
g
o
u
s
 
e
x
c
e
p
t
 
f
o
r
 
G
l
y
3
9
9
A
s
p
.
 
S
I
F
T
 
s
c
o
r
e
 
p
r
e
d
i
c
t
s
 
p
h
e
n
o
t
y
p
i
c
 
e
f
f
e
c
t
;
 
<
0
.
0
5
 
p
r
e
d
i
c
t
e
d
 
t
o
 
b
e
 
d
e
l
e
t
e
r
i
o
u
s
,
 
≥
0
.
0
5
 
t
o
l
e
r
a
t
e
d
.
 
S
I
F
T
 
s
c
o
r
e
 
c
a
n
n
o
t
 
b
e
 
c
a
l
c
u
l
a
t
e
d
 
f
o
r
t
h
e
 
n
o
n
s
e
n
s
e
/
i
n
-
d
e
l
 
v
a
r
i
a
n
t
s
.
 
T
h
e
 
e
f
f
e
c
t
 
o
f
 
t
h
e
 
s
u
b
s
t
i
t
u
t
i
o
n
 
o
n
 
t
h
e
 
p
r
o
t
e
i
n
 
s
t
r
u
c
t
u
r
e
 
w
a
s
 
a
s
s
e
s
s
e
d
 
b
y
 
P
o
l
y
P
h
e
n
-
2
.
 
†
 
P
r
e
s
e
n
t
 
s
t
u
d
y
 
a
n
d
 
p
r
e
v
i
o
u
s
l
y
 
p
u
b
l
i
s
h
e
d
 
[
2
5
]
,
 
‡
 
P
r
e
v
i
o
u
s
l
y
 
p
u
b
l
i
s
h
e
d
 
[
2
5
]
.
Molecular Vision 2012; 18:1548-1557 <http://www.molvis.org/molvis/v18/a160> © 2012 Molecular Vision
15512  unrelated  families  among  which  one  family  showed
incomplete penetrance [25]. The family members of GL1117
were not available for examination. This mutation is common
among Caucasians [35] with a prevalence of 29.3% in the
world.
In  addition,  previous  studies  from  the  laboratory
identified three more mutations Pro370Leu, Gly399Asp, and
Ala427Thr  (Table  2).  Thus,  comprehensive  analysis  of
MYOC coding regions in a cohort of 765 POAG patients from
eastern  India,  including  previous  studies  [25,26],  led  to
identification of 12 mutations in 23 patients.
Synonymous changes in the MYOC coding region: In
addition  to  other  variants,  10  synonymous  changes  were
identified in heterozygous condition only in patients and not
in  controls  (Table  3).  Among  these  variants,  c.1239C>T
(Leu413Leu)  was  predicted  to  undergo  a  change  in  the
MYOC mRNA structure with a variation in structural energy
(∆G) of 15kJ (from −486.66kJ to −471.00kJ) that might affect
the protein stability.
Variants identified in the MYOC promoter region: The
promoter  region  of  MYOC  has  multiple  steroid  hormone
response elements and regulatory motifs [36]. Polymorphisms
in the MYOC upstream region could influence regulation of
its  expression  and  their  possible  consequences  on
predisposition to POAG. Analysis of 1Kb of the proximal
promoter of MYOC in 250 POAG patients and 100 controls
led to the identification of 5 nucleotide variants which are
listed in Table 3. Among these variants −83G>A is widely
reported but −159T>C, −241G>A, and −320C>T represent
novel polymorphisms. No significant difference was observed
in the distribution of alleles among the patients and controls.
The  nucleotide  variant  −190T>C,  i.e  the  4th  base  of  a
consensus putative negative glucocorticoid response element
(nGRE) was identified in a single POAG patient. However,
this change has been previously identified in controls in other
populations [37,38].
DISCUSSION
The study on the eastern Indian POAG cohort (n=765) from
this group led to identification of 12 mutations (5 novel and 7
reported) in MYOC of 23 patients (3%) which is consistent
with the world average (2%–4%). The mutations include 9
nonsynonymous  changes,  2  deletions  and  1  nonsense
mutation, and most of the mutations (9/12) are located in exon
3 which codes for the olfactomedin domain, reported to be
important  for  the  functionality  of  the  protein  [39].  No
significant change was identified in the promoter region of
MYOC.
To  date,  involvement  of  MYOC  in  POAG  has  been
examined mostly in eastern and southern parts of India only.
The report by Chakrabarti et al. [31] in 2005 included 13.5%
patients from western India and 23.5% patients from northern
TABLE 3. POLYMORPHIC AND RARE VARIANTS IN MYOC IN EASTERN INDIAN POAG COHORT.
        Number of
Location Nucleotide change Amino acid change Status Patients (MAF) Controls (MAF)
Promoter −83G>A* - Reported 150/ 250 (0.33) 67/100 (0.38)
  −159T>C* - Novel 12/250 (0.024) 4/100 (0.02)
  −190T>C - Reported 1/250 (0.002) 0/100
  −241G>A* - Novel 18/250 (0.036) 6/100 (0.03)
  −320C>T* - Novel 24/250 (0.048) 10/100 (0.05)
Exon 1 c.98G>A Arg33Lys Novel 1/765 (0.00065) 0/208
  c.227G>A* Arg76Lys† Reported 459/765 (0.33) 139/208 (0.38)
  c.309 C>T Thr103Thr Novel 1/765 (0.00065) 0/208
  c.372 G>C Leu124Leu Novel 1/765 (0.00065) 0/208
  c.419 C>G Thr140Ser Novel 0/208 1/765 (0.00065)
Exon 3 c.816 A>T Arg272Arg Novel 1/765 (0.00065) 0/208
  c.855 G>T Thr285Thr‡ Reported 1/765 (0.00065) 0/208
  c.952C>T Leu318Leu‡ Reported 1/765 (0.00065) 0/208
  c.1041T>C Tyr347Tyr† Reported 18/765 (0.012) 1/208 (0.002)
  c.1053C>T Thr351Thr Reported 1/765 (0.00065) 0/208
  c.1058C>T Thr353Ile‡ Reported 1/765 (0.00065) 0/208
  c.1182C>T Thr394Thr‡ Reported 1/765 (0.00065) 0/208
  c.1185T>G Asp395Glu Novel 1/765 (0.00065) 0/208
  c.1239C>T Leu413Leu Novel 1/765 (0.00065) 0/208
  c.1278C>T Val426Val Novel 1/765 (0.00065) 0/208
From a cohort of 765 POAG patients, 450 DNA samples were screened for the coding region of MYOC in the present study;
the remaining 315 have been analyzed before [25]. Unrelated control subjects (n=208) were enrolled from the same ethnic
background. One kb upstream region of the gene was also examined for variants in 250 patients and 100 control samples. MAF:
Minor Allele Frequency. † Present study and previously published [25], ‡ Previously published [25].
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1553Figure 1. Novel changes identified in myocilin in POAG patients. All the changes were identified in the heterozygous condition. The mutated
base is indicated with an arrowhead in the chromatograms. A: The chromatogram on the left demonstrates location of a synonymous variant
(c.372 G>C, Leu124Leu) and a deletion mutation (c.375, del G, R125SfsX158). On the right, the cartoons show all the known domains of
normal MYOC and the truncated protein resulting from the deletion, including aberrant 33 amino acids at the COOH-terminal end. B: The
chromatogram on the left demonstrates location of a deletion mutation (c.819, del C, D273DfsX344). On the right, the cartoons demonstrate
the known domains of normal MYOC and the truncated protein resulting from the deletion, including aberrant 71 amino acids at the COOH-
terminal end. C: The chromatogram on the left demonstrates location of a nonsynonymous variant (c.992 C>T, Ser331Leu). On the right,
conservation status of the residue (indicated by arrowhead) is shown in homologous protein in other species.
Molecular Vision 2012; 18:1548-1557 <http://www.molvis.org/molvis/v18/a160> © 2012 Molecular Vision
1554India  in  a  cohort  of  251  patients,  but  no  POAG  causing
mutation in MYOC was identified in these two groups. A
complete list of mutations in the MYOC gene identified in the
Indian  population  is  listed  in  the  Indian  Genetic  Disease
Database  [40].  Among  the  identified  genetic  defects,
Gln48His is the most prevalent mutation detected in the Indian
population. Interestingly, this mutation has not been reported
from any other part of the globe.
As  discussed  in  the  results  section,  in  addition  to
nonsynonymous  changes,  two  frame  shift  mutations,  viz.
R125SfsX158 and D273DfsX344, resulting from single base
deletions were identified in patients having a positive family
history  of  glaucoma.  The  mutations  resulted  in  early
termination and formation of truncated proteins lacking the
COOH-terminal  olfactomedin  domain  of  myocilin,  a
functionally  important  region.  To  date,  small  deletion
accounts for 2.3% of the mutations identified in myocilin and
all of them have been marked as glaucoma causing mutations
[41].
Studies done on MYOC suggest that haploinsufficiency
is not a critical mechanism for POAG in individuals with
mutations in the gene. There has been a lack of discernible
phenotype in both Myoc-heterozygous and Myoc null mice
[18].  Also,  absence  of  POAG  in  carriers  with  MYOC
homozygous mutations, in contrast to disease phenotype in
carriers of heterozygous mutations [42], points toward the fact
that disease-causing mutations in humans likely act by gain
of function. The COOH-terminal domain of myocilin is of
functional  importance.  Calpain  binds  in  the  olfactomedin
domain of myocilin [43] and proteolytic cleavage of myocilin
occurs between amino acids Arg226 and Ile227 [39].
Conceptual  translation  of  the  frameshift  mutation
R125SfsX158 in exon 1 produces a mutated protein of 158
amino acids (including aberrant 33 amino acids at the COOH-
terminal  end).  Similarly,  D273DfsX344  in  exon  3  would
produce a 344 amino acid protein with 71 aberrant amino
acids.  These  heterozygous  forms  of  the  mutated  protein
interferes with the proper functioning of the native myocilin
by increasing the secretion of the mutated form and reducing
the secretion of the extracellular processed myocilin, thus
causing  POAG  by  dominant  gain  of  function  mechanism
[44]. In this context, others [45-47] have also demonstrated
that  mutation  or  absence  of  the  olfactomedin  domain  of
myocilin  results  in  a  misfolded  protein  product,  which
suppresses the proper secretion of the protein. This misfolded
protein accumulates in the endoplasmic reticulum [48,49],
causing ER stress and subsequently resulting in cell death
[48-50].  This  proves  that  mutations  in  the  olfactomedin
domain  are  expected  to  give  rise  to  possible  pathogenic
glaucoma phenotypes, and explains preponderance of disease
causing mutations in MYOC exon 3 coding this domain.
This study, according to our knowledge, is the largest
study  to  date  performed  in  a  single  cohort  in  the  Indian
population.  The  involvement  of  the  gene  in  3%  of  the
population is similar to what is reported in the world literature.
The  identification  of  MYOC  mutations  in  probands  and
preclinical  diagnosis  of  the  individuals  at  risk  will  help
clinicians in better management of the disease.
ACKNOWLEDGMENTS
The authors are grateful to the donors who participated in this
study and to Dr. Keya Sen for helping with clinical evaluation
of patients. Ms Ankita Bansal, provided help with PCR and
sequencing of genomic DNA. This study was supported by
grants SIP-007, MLP-0016 and NWP 004 from the Council
of Scientific and Industrial Research (CSIR), India. D.B. is
supported by predoctoral fellowship from CSIR.
REFERENCES
1. Quigley HA. Number of people with glaucoma worldwide. Br
J Ophthalmol 1996; 80:389-93. [PMID: 8695555]
2. Gong G, Kosoko-Lasaki S, Haynatzki G, Lynch HT, Lynch JA,
Wilson MR. Inherited, familial and sporadic primary open-
angle glaucoma. J Natl Med Assoc 2007; 99:559-63. [PMID:
17534014]
3. Loewen N, Fautsch MP, Peretz M, Bahler CK, Cameron JD,
Johnson DH, Poeschla EM. Genetic modification of human
trabecular meshwork with lentiviral vectors. Hum Gene Ther
2001; 12:2109-19. [PMID: 11747600]
4. Seiler  T,  Wollensak  J.  The  resistance  of  the  trabecular
meshwork to aqueous humor outflow. Graefes Arch Clin Exp
Ophthalmol 1985; 223:88-91. [PMID: 4007511]
5. Ray K, Mookherjee S. Molecular complexity of primary open
angle glaucoma: current concepts. J Genet 2009; 88:451-67.
[PMID: 20090207]
6. Gemenetzi M, Yang Y, Lotery AJ. Current concepts on primary
open-angle  glaucoma  genetics:  a  contribution  to  disease
pathophysiology  and  future  treatment.  Eye  (Lond)  2012;
26:355-69. [PMID: 22173078]
7. Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR,
Sunden SL, Nishimura D, Clark AF, Nystuen A, Nichols BE,
Mackey DA, Ritch R, Kalenak JW, Craven ER, Sheffield VC.
Identification  of  a  gene  that  causes  primary  open  angle
glaucoma. Science 1997; 275:668-70. [PMID: 9005853]
8. Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados
M,  Heon  E,  Krupin  T,  Ritch  R,  Kreutzer  D,  Crick  RP,
Sarfarazi  M.  Adult-onset  primary  open-angle  glaucoma
caused  by  mutations  in  optineurin.  Science  2002;
295:1077-9. [PMID: 11834836]
9. Monemi S, Spaeth G, DaSilva A, Popinchalk S, Ilitchev E,
Liebmann J, Ritch R, Heon E, Crick RP, Child A, Sarfarazi
M. Identification of a novel adult-onset primary open-angle
glaucoma (POAG) gene on 5q22.1. Hum Mol Genet 2005;
14:725-33. [PMID: 15677485]
10. Pasutto F, Matsumoto T, Mardin CY, Sticht H, Brandstatter JH,
Michels-Rautenstrauss K, Weisschuh N, Gramer E, Ramdas
WD, van Koolwijk LM, Klaver CC, Vingerling JR, Weber
BH,  Kruse  FE,  Rautenstrauss  B,  Barde  YA,  Reis  A.
Heterozygous  NTF4  mutations  impairing  neurotrophin-4
signaling in patients with primary open-angle glaucoma. Am
J Hum Genet 2009; 85:447-56. [PMID: 19765683]
Molecular Vision 2012; 18:1548-1557 <http://www.molvis.org/molvis/v18/a160> © 2012 Molecular Vision
155511. Vithana  EN,  Nongpiur  ME,  Venkataraman  D,  Chan  SH,
Mavinahalli J, Aung T. Identification of a novel mutation in
the NTF4 gene that causes primary open-angle glaucoma in
a  Chinese  population.  Mol  Vis  2010;  16:1640-5.  [PMID:
20806036]
12. Liu Y, Liu W, Crooks K, Schmidt S, Allingham RR, Hauser
MA.  No  evidence  of  association  of  heterozygous  NTF4
mutations in patients with primary open-angle glaucoma. Am
J Hum Genet 2010; 86:498-9. [PMID: 20215012]
13. Rao KN, Kaur I, Parikh RS, Mandal AK, Chandrasekhar G,
Thomas R, Chakrabarti S. Variations in NTF4, VAV2, and
VAV3 genes are not involved with primary open-angle and
primary angle-closure glaucomas in an indian population.
Invest  Ophthalmol  Vis  Sci  2010;  51:4937-41.  [PMID:
20463313]
14. Acharya M, Mookherjee S, Bhattacharjee A, Bandyopadhyay
AK, Daulat Thakur SK, Bhaduri G, Sen A, Ray K. Primary
role of CYP1B1 in Indian juvenile-onset POAG patients. Mol
Vis 2006; 12:399-404. [PMID: 16688110]
15. Melki R, Colomb E, Lefort N, Brezin AP, Garchon HJ. CYP1B1
mutations in French patients with early-onset primary open-
angle  glaucoma.  J  Med  Genet  2004;  41:647-51.  [PMID:
15342693]
16. Vincent AL, Billingsley G, Buys Y, Levin AV, Priston M,
Trope G, Williams-Lyn D, Heon E. Digenic inheritance of
early-onset glaucoma: CYP1B1, a potential modifier gene.
Am J Hum Genet 2002; 70:448-60. [PMID: 11774072]
17. Kubota R, Kudoh J, Mashima Y, Asakawa S, Minoshima S,
Hejtmancik JF, Oguchi Y, Shimizu N. Genomic organization
of the human myocilin gene (MYOC) responsible for primary
open  angle  glaucoma  (GLC1A).  Biochem  Biophys  Res
Commun 1998; 242:396-400. [PMID: 9446806]
18. Kim BS, Savinova OV, Reedy MV, Martin J, Lun Y, Gan L,
Smith RS, Tomarev SI, John SW, Johnson RL. Targeted
Disruption  of  the  Myocilin  Gene  (Myoc)  Suggests  that
Human Glaucoma-Causing Mutations Are Gain of Function.
Mol Cell Biol 2001; 21:7707-13. [PMID: 11604506]
19. Carbone MA, Ayroles JF, Yamamoto A, Morozova TV, West
SA, Magwire MM, Mackay TF, Anholt RR. Overexpression
of  myocilin  in  the  Drosophila  eye  activates  the  unfolded
protein  response:  implications  for  glaucoma.  PLoS  ONE
2009; 4:e4216. [PMID: 19148291]
20. Perkumas  KM,  Hoffman  EA,  McKay  BS,  Allingham  RR,
Stamer WD. Myocilin-associated exosomes in human ocular
samples. Exp Eye Res 2007; 84:209-12. [PMID: 17094967]
21. Fingert JH, Heon E, Liebmann JM, Yamamoto T, Craig JE, Rait
J, Kawase K, Hoh ST, Buys YM, Dickinson J, Hockey RR,
Williams-Lyn D, Trope G, Kitazawa Y, Ritch R, Mackey DA,
Alward WL, Sheffield VC, Stone EM. Analysis of myocilin
mutations  in  1703  glaucoma  patients  from  five  different
populations.  Hum  Mol  Genet  1999;  8:899-905.  [PMID:
10196380]
22. Kanagavalli  J,  Krishnadas  SR,  Pandaranayaka  E,
Krishnaswamy  S,  Sundaresan  P.  Evaluation  and
understanding of myocilin mutations in Indian primary open
angle glaucoma patients. Mol Vis 2003; 9:606-14. [PMID:
14627955]
23. Sripriya S, Uthra S, Sangeetha R, George RJ, Hemamalini A,
Paul PG, Amali J, Vijaya L, Kumaramanickavel G. Low
frequency of myocilin mutations in Indian primary open-
angle glaucoma patients. Clin Genet 2004; 65:333-7. [PMID:
15025728]
24. Rose  R,  Balakrishnan  A,  Muthusamy  K,  Arumugam  P,
Shanmugam S, Gopalswamy J. Myocilin mutations among
POAG patients from two populations of Tamil Nadu, South
India, a comparative analysis. Mol Vis 2011; 17:3243-53.
[PMID: 22194650]
25. Bhattacharjee A, Acharya M, Mukhopadhyay A, Mookherjee
S, Banerjee D, Bandopadhyay AK, Thakur SK, Sen A, Ray
K.  Myocilin  variants  in  Indian  patients  with  open-angle
glaucoma.  Arch  Ophthalmol  2007;  125:823-9.  [PMID:
17562996]
26. Mukhopadhyay A, Acharya M, Mukherjee S, Ray J, Choudhury
S, Khan M, Ray K. Mutations in MYOC gene of Indian
primary  open  angle  glaucoma  patients.  Mol  Vis  2002;
8:442-8. [PMID: 12447164]
27. Fingert JH, Stone EM, Sheffield VC, Alward WL. Myocilin
glaucoma.  Surv  Ophthalmol  2002;  47:547-61.  [PMID:
12504739]
28. Shimizu  S,  Lichter  PR,  Johnson  AT,  Zhou  Z,  Higashi  M,
Gottfredsdottir  M,  Othman  M,  Moroi  SE,  Rozsa  FW,
Schertzer  RM,  Clarke  MS,  Schwartz  AL,  Downs  CA,
Vollrath  D,  Richards  JE.  Age-dependent  prevalence  of
mutations  at  the  GLC1A  locus  in  primary  open-angle
glaucoma.  Am  J  Ophthalmol  2000;  130:165-77.  [PMID:
11004290]
29. Zode GS, Kuehn MH, Nishimura DY, Searby CC, Mohan K,
Grozdanic SD, Bugge K, Anderson MG, Clark AF, Stone EM,
Sheffield  VC.  Reduction  of  ER  stress  via  a  chemical
chaperone prevents disease phenotypes in a mouse model of
primary  open  angle  glaucoma.  J  Clin  Invest  2011;
121:3542-53. [PMID: 21821918]
30. Rose R, Karthikeyan M, Anandan B, Jayaraman G. Myocilin
mutations among primary open angle glaucoma patients of
Kanyakumari  district,  South  India.  Mol  Vis  2007;
13:497-503. [PMID: 17417611]
31. Chakrabarti S, Kaur K, Komatireddy S, Acharya M, Devi KR,
Mukhopadhyay A, Mandal AK, Hasnain SE, Chandrasekhar
G, Thomas R, Ray K. Gln48His is the prevalent myocilin
mutation  in  primary  open  angle  and  primary  congenital
glaucoma  phenotypes  in  India.  Mol  Vis  2005;  11:111-3.
[PMID: 15723004]
32. Kumar A, Basavaraj MG, Gupta SK, Qamar I, Ali AM, Bajaj
V, Ramesh TK, Prakash DR, Shetty JS, Dorairaj SK. Role of
CYP1B1, MYOC, OPTN, and OPTC genes in adult-onset
primary  open-angle  glaucoma:  predominance  of  CYP1B1
mutations  in  Indian  patients.  Mol  Vis  2007;  13:667-76.
[PMID: 17563717]
33. Zhou Z, Vollrath D. A cellular assay distinguishes normal and
mutant  TIGR/myocilin  protein.  Hum  Mol  Genet  1999;
8:2221-8. [PMID: 10545602]
34. Clark AF, Kawase K, English-Wright S, Lane D, Steely HT,
Yamamoto T, Kitazawa Y, Kwon YH, Fingert JH, Swiderski
RE, Mullins RF, Hageman GS, Alward WL, Sheffield VC,
Stone  EM.  Expression  of  the  glaucoma  gene  myocilin
(MYOC) in the human optic nerve head. FASEB J 2001;
15:1251-3. [PMID: 11344104]
35. Bhattacharjee  A,  Acharya  M,  Mookherjee  S,  Banerjee  S,
Mukhopadhyay A, Banerjee AK, Thakur SKD, Sen A, Ray
K. Role of Myocilin in Glaucoma: Molecular Defects and
Molecular Vision 2012; 18:1548-1557 <http://www.molvis.org/molvis/v18/a160> © 2012 Molecular Vision
1556Possible  Functional  Aberrations  Leading  to  Pathogenesis.
Asian J. Exp. Sci. 2006; 20:97-112.
36. Nguyen TD, Chen P, Huang WD, Chen H, Johnson D, Polansky
JR. Gene structure and properties of TIGR, an olfactomedin-
related  glycoprotein  cloned  from  glucocorticoid-induced
trabecular meshwork cells. J Biol Chem 1998; 273:6341-50.
[PMID: 9497363]
37. Fingert JH, Clark AF, Craig JE, Alward WL, Snibson GR,
McLaughlin M, Tuttle L, Mackey DA, Sheffield VC, Stone
EM. Evaluation of the myocilin (MYOC) glaucoma gene in
monkey  and  human  steroid-induced  ocular  hypertension.
Invest  Ophthalmol  Vis  Sci  2001;  42:145-52.  [PMID:
11133859]
38. Lopez-Martinez  F,  Lopez-Garrido  MP,  Sanchez-Sanchez  F,
Campos-Mollo  E,  Coca-Prados  M,  Escribano  J.  Role  of
MYOC and OPTN sequence variations in Spanish patients
with  primary  open-angle  glaucoma.  Mol  Vis  2007;
13:862-72. [PMID: 17615537]
39. Aroca-Aguilar JD, Sanchez-Sanchez F, Ghosh S, Coca-Prados
M, Escribano J. Myocilin mutations causing glaucoma inhibit
the  intracellular  endoproteolytic  cleavage  of  myocilin
between amino acids Arg226 and Ile227. J Biol Chem 2005;
280:21043-51. [PMID: 15795224]
40. Pradhan S, Sengupta M, Dutta A, Bhattacharyya K, Bag SK,
Dutta C, Ray K. Indian genetic disease database. Nucleic
Acids Res 2011; 39:D933-8. [PMID: 21037256]
41. Hewitt AW, Mackey DA, Craig JE. Myocilin allele-specific
glaucoma  phenotype  database.  Hum  Mutat  2008;
29:207-11. [PMID: 17966125]
42. Morissette  J,  Clepet  C,  Moisan  S,  Dubois  S,  Winstall  E,
Vermeeren D, Nguyen TD, Polansky JR, Cote G, Anctil JL,
Amyot M, Plante M, Falardeau P, Raymond V. Homozygotes
carrying  an  autosomal  dominant  TIGR  mutation  do  not
manifest  glaucoma.  Nat  Genet  1998;  19:319-21.  [PMID:
9697688]
43. Sánchez-Sánchez F, Martinez-Redondo F, Aroca-Aguilar JD,
Coca-Prados  M,  Escribano  J.  Characterization  of  the
intracellular  proteolytic  cleavage  of  myocilin  and
identification of calpain II as a myocilin-processing protease.
J Biol Chem 2007; 282:27810-24. [PMID: 17650508]
44. Aroca-Aguilar JD, Sanchez-Sanchez F, Martinez-Redondo F,
Coca-Prados M, Escribano J. Heterozygous expression of
myocilin glaucoma mutants increases secretion of the mutant
forms and reduces extracellular processed myocilin. Mol Vis
2008; 14:2097-108. [PMID: 19023451]
45. Caballero  M,  Borras  T.  Inefficient  processing  of  an
olfactomedin-deficient  myocilin  mutant:  potential
physiological relevance to glaucoma. Biochem Biophys Res
Commun 2001; 282:662-70. [PMID: 11401512]
46. Jacobson N, Andrews M, Shepard AR, Nishimura D, Searby C,
Fingert JH, Hageman G, Mullins R, Davidson BL, Kwon YH,
Alward  WL,  Stone  EM,  Clark  AF,  Sheffield  VC.  Non-
secretion of mutant proteins of the glaucoma gene myocilin
in cultured trabecular meshwork cells and in aqueous humor.
Hum Mol Genet 2001; 10:117-25. [PMID: 11152659]
47. Kanagavalli  J,  Pandaranayaka  PJ,  Krishnadas  SR,
Krishnaswamy S, Sundaresan P. In vitro and in vivo study on
the secretion of the Gly367Arg mutant myocilin protein. Mol
Vis 2007; 13:1161-8. [PMID: 17679945]
48. Joe  MK,  Sohn  S,  Hur  W,  Moon  Y,  Choi  YR,  Kee  C.
Accumulation of mutant myocilins in ER leads to ER stress
and  potential  cytotoxicity  in  human  trabecular  meshwork
cells. Biochem Biophys Res Commun 2003; 312:592-600.
[PMID: 14680806]
49. Liu Y, Vollrath D. Reversal of mutant myocilin non-secretion
and cell killing: implications for glaucoma. Hum Mol Genet
2004; 13:1193-204. [PMID: 15069026]
50. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J. Aggregated
myocilin  induces  russell  bodies  and  causes  apoptosis:
implications for the pathogenesis of myocilin-caused primary
open-angle glaucoma. Am J Pathol 2007; 170:100-9. [PMID:
17200186]
Molecular Vision 2012; 18:1548-1557 <http://www.molvis.org/molvis/v18/a160> © 2012 Molecular Vision
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China.
The print version of this article was created on 18 June 2012. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
1557